

AMENDMENTS TO THE CLAIMS

1. (CURRENTLY AMENDED) A compound 8 to 50 nucleobases in length targeted to a nucleic acid molecule encoding Ship-1 (SEQ ID NO: 3), wherein said compound specifically hybridizes with said nucleic acid molecule encoding Ship-1 and inhibits the expression of Ship-1.
2. (Original) The compound of claim 1 which is an antisense oligonucleotide.
3. (Original) The compound of claim 2 wherein the antisense oligonucleotide has a sequence comprising SEQ ID NO: 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 58, 59, 61, 62, 66, 67, 69, 70, 73, 74, 75, 76, 79, 81, 82, 83, 84, 85, 86 or 87.
4. (Original) The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified internucleoside linkage.
5. (Original) The compound of claim 4 wherein the modified internucleoside linkage is a phosphorothioate linkage.
6. (Original) The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified sugar moiety.
7. (Original) The compound of claim 6 wherein the modified sugar moiety is a 2'-O-methoxyethyl sugar moiety.
8. (Original) The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified nucleobase.
9. (Original) The compound of claim 8 wherein the modified nucleobase is a 5-methylcytosine.
10. (Original) The compound of claim 2 wherein the antisense oligonucleotide is a chimeric oligonucleotide.
11. (CURRENTLY AMENDED) A compound 8 to 50 nucleobases in length which specifically hybridizes with at least an 8-nucleobase portion of an active site on a nucleic acid molecule encoding Ship-1 (SEQ ID NO: 3).

12. (Original) A composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier or diluent.
13. (Original) The composition of claim 12 further comprising a colloidal dispersion system.
14. (Original) The composition of claim 12 wherein the compound is an antisense oligonucleotide.
- 15-20. (CANCELED)
21. (NEW) The compound of claim 1 which is 20 to 50 nucleobases in length.
22. (NEW) The compound of claim 1 which comprises at least 40% inhibition of expression of Ship-1.
23. (NEW) The compound of claim 11 which is 20 to 50 nucleobases in length.
24. (NEW) The compound of claim 11 which comprises at least 40% inhibition of expression of Ship-1.